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Abstract
Dehydrozingerone analogs and related compounds were screened as potential antitumor promoters
by using the in vitro short-term 12-O-tetradecanphorbol-13-acetate (TPA)-induced Epstein-Barr
virus early antigen (EBV-EA) activation assay. Among 40 synthesized compounds, the prenylated
analogs 16 and 34–36 showed the most significant and promising activity (100% inhibition of
activation at 1×10 3 mol ratio/TPA, and 82–80%, 37–35%, 13–11% inhibition at 5×102, 1×102,
1×10 mol ratio/TPA, respectively) in this screening. Their activity profiles were comparable to
that of the reference standard curcumin. While a prenyl moiety conferred potent chemopreventive
activity, an extended prenyl unit such as a farnesyl moiety did not improve activity. Because in
vitro inhibitory effects in this assay generally correlate well with in vivo inhibitory effects on
tumor promotion, our results strongly suggested that prenylated 16 and 34–36 are likely to be
promising antitumor promoters.
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1. Introduction
The natural product dehydrozingerone (DZ, 1) is the “half analog” of curcumin (2) (Figure
1), which is known to have potent anti-oxidant, anti-inflammatory, and antitumor promoting
(chemopreventive) activities [1,2]. Curcumin inhibits epidermal inflammation in mice and
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced tumor promotion in mouse skin [3].
Structure-activity relationship (SAR) correlations of curcumin analogs as antitumor
promoting agents have also been investigated [4,5]. Dehydrozingerone (1) and isoeugenol
(3), which have similar catechol skeletons, but different alkenyl side chains, had stronger
antitumor promotion effects than curcumin [6]. In the search for antitumor promoters from
natural sources, the antitumor promoting properties of phenylpropanoids have also been
reported [7–9]. The above evidence strongly supports the use of 1 as a lead to develop novel
antitumor promoters and to further explore the structural features necessary for
chemopreventive activity. Because certain natural products and synthetic compounds
containing a prenyl moiety showed strong activity against the Epstein-Barr virus early
antigen (EBV-EA) activation induced by TPA in Raji cells [10–14], prenyl derivatives of 1
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paper, we report the synthesis and SAR study of dehydrozingerone analogs as
chemopreventive agents.
2. Results and discussion
All compounds were previously synthesized [15]. Figure 2 shows the structures of analogs
4–11, which are derivatives of 1, and of the related chalcones 12–15, in which the terminal
methyl group is replaced by phenyl. Figure 3 shows the structures of analogs 16–33, in
which various types of alkyl and alkenyl groups were added to the C-4’ alcohol of 1 and 3,
as well as four additional prenyloxy derivatives 34–37. The structures of methylated and
prenylated curcumins (38 and 39, respectively) are shown in Figure 4. All analogs were
evaluated in vitro as inhibitors of EBV-EA activation induced by TPA in Raji cells [16–18],
and the inhibitory data are shown in Tables 1 and 2. Figure 5 indicates the typical
fluorescent finding of EBV-EA activation in Raji cell through the fluorescence microscope.
Compounds with 3,4-disubstituted benzalacetone structures (1, 5, and 8) showed slightly
better activity than compounds with other disubstitution patterns (e.g. 2,3- or 2,4-). The data
for 12–15 indicated that a phenyl group at C4 decreased the activity. No remarkable
difference was observed between methoxy and ethoxy groups (1 vs. 8 and 4 vs. 9).
However, by comparing 10 and 11 with 1 and 4–9, the presence of fluorine on the benzene
ring might decrease the activity.
Compounds 16–24 (dehydrozingerone analogs), 25–33 (isoeugenol analogs), 34–37
(prenylated analogs), and 38 and 39 (curcumin analogs) were also tested using an in vitro
synergistic assay on EBV-EA activation induced by TPA. The inhibitory effects of tested
compounds and the associated viability of Raji cells are shown in Table 2. Curcumin and 3
were used as positive controls. In this assay, all compounds showed inhibitory effects on
EBV-EA activation without high cytotoxicity on Raji cells. At high concentrations (1×103
mol ratio), dehydrozingerone (16–24 and 34–37), isoeugenol (25–33), and curcumin (38, 39)
derivatives showed 100% inhibition, and at lower concentrations, were as or more potent
than the parent compounds. The prenylated analogs, 16 and 25, showed significant potency
compared with other alkylated analogs in the respective series (see 16–24 for
dehydrozingerone analogs, and 25–33 for isoeugenol analogs). Prenylated dehydrozingerone
analogs 34–37 showed comparable activity with 16, which showed the best activity in the
alkylated series. These findings support the reported conclusions that a prenyl moiety is
important for optimal inhibitory effects on EBV-EA activation [7–9]. Compound 37 was
less active than 16 and 34–36, indicating that fluorine does not affect the activity. Although
analog 19 containing a geranyl group (two prenyl units), was more active than 20 and 29
with farnesyl groups (three prenyl units), it was less active compared with other analogs in
the dehydrozingerone series. Compounds 17, 18, 22–24 and 26, 27, 31, 32, which contain
allyl, 2-butenyl, ethyl, propyl, and isopentyl substituents, respectively, showed similar
activity, while methylated compounds 21 and 30 showed slightly lower activity. When
analogs with structurally similar alkyl and alkenyl groups were compared, (16 vs 24, 17 and
18 vs 23), the presence of a double bond did not seem to affect the activity.
In summary, prenylated dehydrozingerone 16 and its analogs 34–36 showed the most
significant and promising activity in this screening (100% inhibition of activation at 1×103
mol ratio/TPA, and 82–80%, 37–35%, 13–11% inhibition at 5×102, 1×102, 1×10 mol ratio/
TPA, respectively). While a prenyl moiety conferred potent chemopreventive activity, an
extended prenyl unit such a farnesyl moiety did not improve activity. Hydrophobicity might
be important for inhibition of TPA-induced EBV-EA activation. Because in vitro inhibitory
effects in this assay generally correlate well with in vivo inhibitory effects on tumor
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promotion [4,5,19,20], our results suggested that 16 and 34–36 are promising antitumor
promoters and further in vivo investigations are now in progress.
3. Experimental
3.1 In vitro EBV-EA activation experiments
EBV-EA positive serum from a patient with nasopharyngeal carcinoma (NPC) was a gift
from Professor H. Hattori, Department of Otorhinolaryngology, Kobe University. The EBV
genome carrying lymphoblastoid cells (Raji cells derived from Burkitt’s lymphoma) were
cultured in 10% fetal bovine serum (FBS) in RPMI-1640 medium (Sigma R8758, USA).
Spontaneous activation of EBV-EA in our subline of Raji cells was less than 0.1%. The
inhibition of EBV-EA activation was assayed using Raji cells (virus non-producer type) as
described below. The cells were incubated at 37°C for 48 h in 1 mL of medium containing
n-butyric acid (4 mM), TPA [32 pM = 20 ng in 2 μL dimethyl sulfoxide (DMSO)] and
various amounts of the test compounds dissolved in 2 μL of DMSO. Smears were made
from the cell suspension. The EBV-EA inducing cells were stained by the means of an
indirect immunofluorescence technique. In each assay, at least 500 cells were counted, and
the number of stained cells (positive cells) was recorded. Triplicate assays were performed
for each compound. The average EBV-EA induction of the test compound was expressed as
a ratio relative to the control experiment (100%), which was carried out with n-butyric acid
(4 mM) plus TPA (32 pM). EBV-EA induction was ordinarily around 35%. The viability of
treated Raji cells was assayed by the Trypan blue staining method. The cell viability of the
TPA positive control was greater than 80%. Therefore, only these compounds that induced
less than 80% (% of control) of the EBV-active cells (those with a cell viability of more than
60%) were considered able to inhibit the activation caused by promoter substances.
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Structures of Dehydrozingerone (1), Curcumin (2), and Isoeugenol (3)
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Structures of Deydrozingerone Analogs
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Structures of Dehydrozingerone (16–24, 34–37) and Isoeugenol (25–33) Analogs
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Curcumin Analogs 38 and 39
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Figure 5. Typical fluorescent findings of EBV-EA activation
a) EBV-EA expression by treatment with TPA; b) EBV-EA expression was reduced by
Curcumin; c) No EBV-EA expression was observed without TPA.
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